# Medy-Tox clinical trials: 49 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 49 trials with Medy-Tox as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Medy-Tox: 49 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/medy-tox

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 49
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 49, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| January 18, 2022 | NCT05195112 | Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat | Medy-Tox | Phase 3 | Completed | Submental Fat | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05195112) |
| December 20, 2021 | NCT05164003 | CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase1) | Medy-Tox | Phase 1 | Completed | Muscle Spasticity | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05164003) |
| August 3, 2020 | NCT04496427 | Observational Study to Determine the Efficacy and Safety of Potenfill for Temporary Penile Enhancement | Medy-Tox | Observational | Completed | Penile Enhancement | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04496427) |
| February 24, 2020 | NCT04281745 | Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX® | Medy-Tox | Phase 4 | Unknown | Glabellar Frown Lines | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04281745) |
| November 8, 2019 | NCT04157686 | MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL) | Medy-Tox | Phase 3 | Completed | Glabellar Lines, Lateral Canthal Lines | 957 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04157686) |
| October 30, 2019 | NCT04144049 | A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat | Medy-Tox | Phase 2 | Completed | Submental Fat | 176 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04144049) |
| October 29, 2019 | NCT04143854 | Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines | Medy-Tox | Phase 2 | Completed | Lateral Canthal Lines | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04143854) |
| October 29, 2019 | NCT04143815 | Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines | Medy-Tox | Phase 2 | Completed | Glabellar Frown Lines | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04143815) |
| October 3, 2019 | NCT04113941 | Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive Bladder | Medy-Tox | Phase 3 | Unknown | Overactive Bladder | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04113941) |
| July 5, 2019 | NCT04007211 | Pivotal Clinical Study to Assess the Anti-adhesive Effect and Safety of ABT13107 Applied to Postoperative Intrauterine | Medy-Tox | Not applicable | Completed | Postoperative Adhesion of Uterus | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04007211) |
| April 9, 2019 | NCT03908580 | MEDITOXIN® Treatment in Subjects With Post-Stroke Upper Limb Spasticity | Medy-Tox | Phase 4 | Completed | Spasticity, Muscle | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03908580) |
| April 9, 2019 | NCT03908008 | Efficacy and Safety Study of MT10107 in the Treatment of Glabella Line | Medy-Tox | Phase 3 | Completed | Glabellar Frown Lines | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03908008) |
| April 5, 2019 | NCT03905304 | Efficacy and Safety of MEDITOXIN® in Cervical Dystonia | Medy-Tox | Phase 3 | Completed | Cervical Dystonia | 152 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03905304) |
| April 5, 2019 | NCT03905291 | Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy Subjects | Medy-Tox | Phase 1 | Completed | Healthy Volunteers | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03905291) |
| March 28, 2019 | NCT03894748 | Efficacy and Safety Study of MT10109L in the Treatment of Glabella Line(Including a Preliminary Study to Evaluate Safety of MT10109L) | Medy-Tox | Phase 2/3 | Completed | Glabella Line Severity | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03894748) |
| February 15, 2019 | NCT03840070 | The Efficacy and Safety of Repeat-dose Potenfill for Temporary Penile Enhancement | Medy-Tox | Not applicable | Completed | Penile Girth Enhancement, Penile Enhancement | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03840070) |
| February 12, 2019 | NCT03837561 | The Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar Lines | Medy-Tox | Phase 3 | Completed | Glabellar Frown Lines | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03837561) |
| January 8, 2019 | NCT03796351 | Pharmacodynamic and Safety of MT10107(Botulinum Type A Neurotoxin) in Comparison to BOTOX® | Medy-Tox | Phase 1 | Completed | Healthy Volunteers | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03796351) |
| January 8, 2019 | NCT03795922 | MT10109L in the Treatment of Glabellar Lines | Medy-Tox | Phase 3 | Completed | Glabellar Lines | 234 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03795922) |
| December 24, 2018 | NCT03785145 | MT10109L in the Treatment of Lateral Canthal Lines | Medy-Tox | Phase 3 | Completed | Lateral Canthal Lines | 235 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03785145) |
| November 30, 2018 | NCT03760198 | Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Primary Axillary Hyperhidrosis | Medy-Tox | Phase 3 | Completed | Hyperhidrosis Primary Focal Axilla | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03760198) |
| November 30, 2018 | NCT03759743 | Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject | Medy-Tox | Not applicable | Completed | Overweight | 97 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03759743) |
| November 27, 2018 | NCT03754413 | Neuramis® Volume Lidocaine for Volume Augmentation in the Mid-Face | Medy-Tox | Not applicable | Completed | Mid Face Volume Loss | 236 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03754413) |
| November 26, 2018 | NCT03753152 | Neuramis® Deep Lidocaine Compared to YVOIRE® Volume Plus for Correction of Nasolabial Folds | Medy-Tox | Not applicable | Completed | Nasolabial Folds | 370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03753152) |
| November 7, 2018 | NCT03732833 | MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines | Medy-Tox | Phase 3 | Completed | Lateral Canthal Lines, Glabellar Lines | 425 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03732833) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 7 |
| Phase 2 | 6 |
| Phase 2/3 | 1 |
| Phase 3 | 21 |
| Phase 4 | 6 |
| Not applicable | 7 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 47 |
| Unknown | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Muscle Spasticity | 6 |
| Urinary Bladder, Overactive | 2 |
| Torticollis | 2 |
| Benign essential blepharospasm | 2 |
| Masticatory Muscles, Hypertrophy of | 2 |
| Hyperhidrosis | 1 |
| Overweight | 1 |
| Dystonia | 1 |
| Dystonic Disorders | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Meat wholesalers in the United States](https://specstream.ai/data/businesses/meat-wholesalers/united-states)
- [B2B cleaning and waste management companies in the United States](https://specstream.ai/data/businesses/b2b-cleaning-and-waste-management-companies/united-states)
- [Landscape architecture firms in the United States](https://specstream.ai/data/businesses/landscape-architecture-firms/united-states)
- [American restaurants in the United States](https://specstream.ai/data/businesses/american-restaurants/united-states)
- [Instrumentation engineers in the United States](https://specstream.ai/data/businesses/instrumentation-engineers/united-states)
- [Wholesalers in the United States](https://specstream.ai/data/businesses/wholesalers/united-states)
